- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00459251
Pharmacogenetics Study in Taiwan's Ethnic Groups
The Pharmacogenetics Study of Drug-Metabolising Enzyme Genetic Polymorphisms in Aboriginal and Minnan/Hakka Ethnic Groups in Taiwan
Study Overview
Status
Conditions
Detailed Description
It has been shown that the same medication causes different responses in different individuals. In addition to environments, diets, and physical conditions, the genetic variations play an important role in the various responses. For instant, genetic variations in drug-metabolism enzymes may be responsible to different abilities in drug metabolism. Some people have higher drug-metabolizing enzyme activity for certain drug and may need higher dose to reach the effective therapy; some are poor in metabolizing the same drug, and may cause adverse drug reactions. Genetic variation also may cause different functions of the cell transporters. The most notable example is that some tumor cells have a kind of transporters called p-glycoprotein which can pump out the anti-tumor drugs to extracellular, and it turns the tumor cells become resistant to the drugs. Hence, if we can elucidate the gene variation of each individual, we can give each individual different therapy based on their genetic variations. This approach is called 「individualized medicine」.
In order to reach the goal of individualized medicine, many studies have been focused on drug-metabolizing enzyme genetic variations between races or ethnicities. Especially, single nucleotide polymorphism provides a very important basis to clinical medication. N- acetyltransferase 2 (NAT2) is one kind of drug-metabolizing enzymes and its single nucleotide polymorphisms have remarkable effect on drug-metabolism. Only 10~30 % are slow acetylators in Asian population, but 40~70% are found in Caucasian population. Cytochrome P450 (CYP450,CYP) is another important drug-metabolizing enzyme family. Among the family, the CYP2C9, CYP2C19, and CYP2D6 play key roles on drug metabolism. Many literatures showed that all the three enzymes have various distributions of SNPs in different races. It indicates that different races may have different abilities in drug-metabolizing enzymes. Therefore, it is important to provide a strategy to overcome the difficulties in individualized medicine.
In the previous studies, scientists often take Chinese as the representatives of Asian people and the Minnan/ Hakka or so-called Han people as the subjects when study the Taiwan ethnicity. The genetic variations in the Taiwan aborigines are poorly investigated. It has been showed that remarkable genetic variations in human leukocyte antigen (HLA) between Taiwan aborigines and Minnan/ Hakka by Lin ML and her colleagues. They are highly homogenous within each tribe, but diversified among the different tribes due to long-term isolation. Therefore, we expect to establish a database of genetic variations in drug-metabolism enzymes among these groups in order to use as the basis for clinical medication. This study includes seven groups, and each of them has 50 independent samples for drug-metabolizing enzyme genetic polymorphism analysis. The important enzymes, CYP2C9, CYP2C19, CYP2D6 and NAT2, etc., are studied in this project. ABI 7900HT instrument and traditional polymerase chain reaction (PCR) - restriction fragment length polymorphism (RFLP) both are used for SNPs analysis, and gene sequence also would be used to confirm the results.
Study Type
Enrollment
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 100
- Mackay Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- This study includes seven groups, and each of them has 50 independent samples for drug-metabolizing enzyme genetic polymorphism analysis.
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Li-Jiuan Shen, Ph.D., School of Pharmacy, National Taiwan University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- MMH-I-S-304
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet